InhaleRx Ltd: A Focus on Health Technology Innovation

InhaleRx Limited, a health technology company headquartered in Melbourne, Australia, continues to make strides in the development and commercialization of medical diagnostic and monitoring technologies. The company is dedicated to creating solutions that aid in the management, diagnosis, and evaluation of chronic diseases, as well as the evaluation of skin diseases. As of June 1, 2025, InhaleRx’s stock closed at 0.03 AUD on the ASX All Markets, reflecting a market capitalization of 5,763,101 AUD.

Recent Stock Performance

InhaleRx’s stock has experienced fluctuations over the past year. The 52-week high was recorded at 0.05 AUD on October 17, 2024, while the 52-week low was 0.018 AUD on April 16, 2025. These figures highlight the volatility in the health care technology sector and underscore the challenges and opportunities faced by companies like InhaleRx.

Company Overview

InhaleRx Limited operates within the health care technology industry, focusing on innovative solutions that address critical needs in chronic disease management and skin disease evaluation. The company’s commitment to advancing medical technology is evident in its product offerings and strategic initiatives aimed at improving patient outcomes.

Market Presence

Listed on the ASX All Markets, InhaleRx provides investors with an opportunity to engage with a company at the forefront of health care technology. The company’s presence on this exchange underscores its significance in the sector and its potential for growth and innovation.

For more detailed information about InhaleRx Limited and its offerings, interested parties can visit the company’s website at www.inhalerx.com.au .